Shares of Hims & Hers Health Inc. moved sharply higher this week as the company and Novo Nordisk A/S resolved a legal confrontation that had weighed on investor sentiment around Hims’s weight-loss drug business.
On Friday the stock opened with a notable jump and later eased to a gain of roughly 2% shortly after 10:00 AM. That advance added to a 51% rise logged for the week through Thursday’s close. Over the most recent four trading sessions the shares rose in three, reaching a one-month high during the week.
The uptick followed an announcement earlier in the week in which Hims said it would enter into a partnership with Novo to sell the drugs Ozempic and Wegovy on Hims’s platform. As part of the agreement, Novo agreed to withdraw a lawsuit it had filed against Hims last month.
Under the terms disclosed by the companies, Hims will cease advertising compounded versions of Novo’s medicines. At the same time Hims will continue to provide Ozempic and Wegovy through its platform when a physician determines a patient requires those medications.
The current deal comes after Novo terminated its prior partnership with Hims in June, citing what Novo described as deceptive marketing. Novo executives at that time said Hims had not done enough to curb broad advertising of compounded alternatives to the weight-loss drugs, prompting investor concern over Hims’s business and the prospect of legal action from the Danish pharmaceutical company.
Investor unease intensified earlier this year when Novo filed suit alleging that Hims had introduced a copycat version of the Wegovy pill. Hims subsequently removed that product from the market following regulatory warnings and threats.
Market context
- Hims’s stock performance this week represents a rebound from recent declines tied to regulatory and legal scrutiny of its weight-loss product strategy.
- The agreement with Novo resolved a key legal dispute and clarified conditions under which Hims may sell brand-name obesity treatments on its platform.
- Trading activity this week included gains in three of four sessions, contributing to a one-month high for the shares.
What remains limited in public disclosures
The companies disclosed the broad terms related to advertising and product availability, and that the lawsuit would be withdrawn; other contractual details and financial terms were not provided in the statements summarized here.